ImQuest BioSciences and Arisyn Therapeutics Announce Strategic Partnership to Develop...

ImQuest BioSciences and Arisyn Therapeutics Announce Strategic Partnership to
Develop Infectious Disease and Cancer Drugs

FREDERICK, Md., April 29 /PRNewswire/ -- ImQuest BioSciences and Arisyn
Therapeutics jointly announced today that they have entered into a strategic
drug development partnership to provide support necessary to develop Arisyn's
portfolio of novel inhibitors for the treatment of infectious disease and
cancer. Arisyn has recently announced its acquisition of a series of
inhibitors with demonstrated preclinical efficacy against HIV, HCV, HTLV-I,
influenza virus, herpes viruses and cancer. These inhibitors were originally
discovered and developed by The Proctor & Gamble Company. Lead molecules from
the portfolio have already been evaluated in Phase 1 human clinical trials for
the treatment of HIV and cancer, and an IND-application has been prepared for
submission to the FDA to initiate trials for HCV therapy.

"The Arisyn compounds represent an entirely new treatment paradigm by
effectively suppressing the ability of the HIV or HCV-infected cells to act as
the factories of progeny virus production," stated Robert W. Buckheit, Jr.,
Ph.D., Director of Research and Development for Arisyn and President and Chief
Scientific Officer of ImQuest BioSciences. "The compounds have proven efficacy
and safety in preclinical studies and their successful development will be of
immense benefit to the millions of individuals living with HIV and HCV
infection."

ImQuest BioSciences, a Contract Research service provider specializing in the
discovery and development of anti-infective and anti-cancer agents, will
provide all required support to initiate human clinical trials with lead
products ATI-0312 for HIV and ATI-0810 for HCV and will initiate mechanistic
studies to define the unique virus transcription inhibitory mechanism of
action of the class of inhibitors. ImQuest will also lead Arisyn's efforts to
develop next generation inhibitors from structure activity relationship
studies and target-based drug design programs.

"This partnership is an important step in the development of our portfolio.
ImQuest BioSciences brings a broad range of expertise and a wealth of
experience to Arisyn," said Eric Zucco, President of Arisyn. "After years of
pre-clinical evaluations, we now look to Imquest BioSciences to guide these
compounds into and through human clinical trials."

About Arisyn Therapeutics Inc.
Arisyn Therapeutics Inc. is a privately held biotechnology company focused on
the clinical development of small molecule therapeutics for infectious
diseases and cancer. Arisyn's strategy is to develop novel inhibitors with
unique mechanisms of action for chronic diseases without effective therapeutic
options such as HIV, hepatitis, and cancer. Arisyn Therapeutics Inc. is based
in Frederick, Maryland and is on the web at http://www.Arisyn.com.

About ImQuest BioSciences, Inc.
ImQuest BioSciences, a privately held U.S. company located in Frederick,
Maryland is a leading provider of anti-infective therapeutic and microbicide
development and anti-cancer services to the biotechnology and pharmaceutical
industry. ImQuest has broad based capabilities to assist companies with the
discovery and preclinical development of new therapeutics, vaccines and
preventatives, as well as the management of IND-directed programs for the
evaluation of active products in human clinical trials. ImQuest is on the web
at http://www.imquest.com.

SOURCE ImQuest Life Sciences, Inc.

Dr. Robert Buckheit of ImQuest BioSciences, Inc., +1-301-696-0274